Free Trial

Ernexa Therapeutics (ERNA) Competitors

Ernexa Therapeutics logo
$1.95 -0.15 (-7.14%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$2.00 +0.05 (+2.31%)
As of 07/25/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ERNA vs. IZTC, ANL, SCLX, UNCY, ADVM, IFRX, INMB, ATNM, KRON, and RENB

Should you be buying Ernexa Therapeutics stock or one of its competitors? The main competitors of Ernexa Therapeutics include Invizyne Technologies (IZTC), Adlai Nortye (ANL), Scilex (SCLX), Unicycive Therapeutics (UNCY), Adverum Biotechnologies (ADVM), InflaRx (IFRX), INmune Bio (INMB), Actinium Pharmaceuticals (ATNM), Kronos Bio (KRON), and Renovaro (RENB). These companies are all part of the "pharmaceutical products" industry.

Ernexa Therapeutics vs. Its Competitors

Invizyne Technologies (NASDAQ:IZTC) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Invizyne Technologies has higher earnings, but lower revenue than Ernexa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
Ernexa Therapeutics$580K24.74-$44.54M-$8.31-0.23

Invizyne Technologies has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
Ernexa Therapeutics -7,652.75%N/A -285.71%

In the previous week, Invizyne Technologies and Invizyne Technologies both had 1 articles in the media. Ernexa Therapeutics' average media sentiment score of 1.87 beat Invizyne Technologies' score of 1.11 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Invizyne Technologies Positive
Ernexa Therapeutics Very Positive

70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ernexa Therapeutics beats Invizyne Technologies on 4 of the 6 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ERNA vs. The Competition

MetricErnexa TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.47M$2.50B$5.70B$9.50B
Dividend YieldN/A1.75%4.60%4.01%
P/E Ratio-0.239.0528.1020.05
Price / Sales24.74592.30429.3789.38
Price / CashN/A165.2136.2258.56
Price / Book3.905.168.665.87
Net Income-$44.54M$30.99M$3.25B$258.55M
7 Day Performance-1.52%7.74%4.22%3.73%
1 Month Performance2.63%16.27%10.51%11.75%
1 Year Performance-92.82%-1.88%34.40%18.03%

Ernexa Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ERNA
Ernexa Therapeutics
1.097 of 5 stars
$1.95
-7.1%
N/A-92.8%$15.47M$580K-0.2310Positive News
Gap Up
High Trading Volume
IZTC
Invizyne Technologies
N/A$9.25
flat
N/AN/A$57.83MN/A0.0029News Coverage
Gap Up
ANL
Adlai Nortye
1.8974 of 5 stars
$1.55
+2.0%
$9.00
+480.6%
-57.6%$57.20M$5M0.00127
SCLX
Scilex
2.3836 of 5 stars
$8.16
-5.2%
$455.00
+5,479.4%
-79.9%$56.67M$56.59M-0.2880News Coverage
High Trading Volume
UNCY
Unicycive Therapeutics
3.0066 of 5 stars
$4.51
+0.1%
$60.00
+1,231.9%
+10.7%$56.64M$680K-0.889
ADVM
Adverum Biotechnologies
4.5236 of 5 stars
$2.72
+0.2%
$23.80
+776.6%
-66.6%$56.40M$1M-0.42190News Coverage
Positive News
IFRX
InflaRx
2.4447 of 5 stars
$0.84
-2.5%
$6.60
+689.5%
-41.3%$56.39M$180K-1.0260
INMB
INmune Bio
2.3077 of 5 stars
$2.37
-0.6%
$18.40
+678.0%
-68.0%$55.74M$10K-1.2210Positive News
Upcoming Earnings
ATNM
Actinium Pharmaceuticals
2.4484 of 5 stars
$1.74
+2.7%
$4.00
+130.5%
N/A$54.13MN/A-1.2530
KRON
Kronos Bio
N/A$0.88
+1.5%
$1.63
+84.7%
-34.3%$53.72M$9.85M-0.82100
RENB
Renovaro
2.2249 of 5 stars
$0.31
+0.6%
N/A-75.3%$53.36MN/A-0.4020

Related Companies and Tools


This page (NASDAQ:ERNA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners